Triple‐negative breast cancer in Hispanic patients

Breast Cancer Clinic, National Cancer Institute (INCan), Mexico City, Mexico.
Cancer (Impact Factor: 4.9). 03/2011; 117(16):3658-69. DOI: 10.1002/cncr.25961
Source: PubMed

ABSTRACT Triple-negative breast cancer (TNBC) is defined as breast cancer that is negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. TNBC represents 15% of all invasive breast cancers, but some studies have suggested that its prevalence differs between races. To the authors' knowledge, no previous studies have determined the prevalence of TNBC and its risk factors among Hispanic women.
The authors identified 2074 Hispanic women with breast cancer who attended the National Cancer Institute in Mexico City from 1998 to 2008. All histopathologic and immunohistochemical diagnoses were rereviewed by a breast cancer pathologist. The prevalence of TNBC, its association with clinicopathologic characteristics, and its prognostic impact were determined.
The median patient age at diagnosis (±standard deviation) was 50 ± 12 years. The overall prevalence of TNBC was 23.1%. Younger age (P < .001), premenopausal status (P = .002), increased parity (P = .029), hormonal contraceptive use (P = .04) high histologic grade (P < .001), and advanced disease (P < .001) were associated independently with TNBC. Postmenopausal patients who had a body mass index (BMI) <25 kg/m(2) (P = .027) or <30 kg/m(2) (P < .001) were more likely to have TNBC. In multivariate analysis, patients with TNBC had a higher risk of locoregional recurrence (LRR), lower disease-free survival (DFS) (hazard ratio, 1.62; 95% confidence interval, 1.13-2.32; P = .009), and a lower cancer-specific survival (CSS) rate (hazard ratio, 1.66; 95% confidence interval, 1.20-2.30; P = .002) than patients with non-TNBC.
The median age at diagnosis of Hispanic women with breast cancer was 11 years younger than the average age reported in the United States. The prevalence of TNBC in this study population was higher than that reported in white women with breast cancer. TNBC was associated with a higher risk of LRR and with lower DFS and CSS than those in patients with non-TNBC.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The immunophenotype of BRCA-associated breast cancer has been studied in predominantly non-Hispanic whites (NHW). We evaluated the pathological characteristics of BRCA-associated invasive breast cancer in Hispanics. A case-control study was conducted on breast cancers from Hispanic and NHW women who enrolled in an IRB-approved registry and underwent BRCA gene analysis. BRCA negative controls (41 Hispanic, 39 NHW) were matched on age and ethnicity to BRCA positive cases (39 Hispanic, 35 NHW). A tissue array was constructed to characterize the expression of estrogen receptor (ER), progesterone receptor (PR), HER2, Ki-67 and p53 by immunohistochemistry. Mean age at diagnosis was 37.1 years (range 24-59) for Hispanics (80% with Mexican ancestry) and 40.1 years (range 21-63) for NHW (P = 0.03). Hispanic BRCA1 cases were more likely than BRCA negative controls to have tumors that were ER-negative (P < 0.001) and PR-negative (P = 0.001), had higher levels of Ki-67 (P = 0.001) and p53 expression, and lower levels of HER2 overexpression. When stratified by genes, there were no significant differences in expression of ER, Ki-67, HER2, and p53 by ethnicity among mutation carriers. However, a significantly higher proportion of BRCA-positive Hispanics had PR-negative tumors compared to BRCA-positive NHW (80 vs. 57%, OR = 2.9, 95% CI 1.0-8.1, P = 0.04). Hispanic BRCA-associated breast cancers were found to have the unique immunophenotype associated with BRCA mutations; however, there was a trend toward a difference in PR expression among Hispanic BRCA1 and BRCA2 cases. Additional research on the molecular mechanisms involved in the loss of PR in this population is warranted as it could have important implications for the treatment and prevention of breast cancer in Hispanics.
    Breast Cancer Research and Treatment 05/2011; 130(1):281-9. DOI:10.1007/s10549-011-1570-7 · 4.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Triple-negative breast cancer (TNBC) demonstrates lack of expression of hormone receptors and human epidermal growth factor receptor. However, there is no targeted therapy for TNBC. The authors analyzed 29 TNBC cases for Notch-1 and Notch-4 biomarker expression and subcellular location, Ki67 proliferation rate, and relevant clinical/survival data. Results demonstrated an unfavorable Ki67 rate in 90% of cases, Notch-1 expression in tumor and endothelial cells in 100% of cases, and Notch-4 expression in tumor cells in 73% of cases and endothelial cells in 100% of cases. Additionally, subcellular localization of Notch-1 and Notch-4 was predominantly nuclear and cytoplasmic. In conclusion, (a) the majority of TNBCs are high-grade infiltrating ductal carcinomas with high Ki67 proliferation rate and (b) both Notch-1 and Notch-4 receptors are overexpressed in tumor and vascular endothelial cells with subcellular localization different from that of hormone-positive breast cancer. Targeting Notch signaling with gamma secretase inhibitors should to be explored to further improve the survival rate of TNBC patients.
    International Journal of Surgical Pathology 11/2011; 20(2):139-45. DOI:10.1177/1066896911427035 · 0.96 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To assess the different expression profiles of ductal BC in Mexican women based on IHC analysis of three markers (ER, PR, and HER2) and to compare them between women with EOBC (≤35 years of age at diagnosis) and patients over 35 years. Methodology: All consecutive, new cases of invasive ductal carcinoma not otherwise specified, registered at the Pathology Department files were selected for study. General frequencies of each marker were determined and different profiles in tumor tissue samples were obtained. Results: 506 tumor samples were studied; 43 of them from women with EOBC (8.5%). The IHC profiles of tumors were: triple negative, 19.1%; HER2, 16.6%; luminal A, 56.3%, and luminal B, 8%. Women with EOBC and older patients have significantly different profiles. The triple negative, the HER2-overexpressing, and the luminal B, ER+PR- profiles were more frequent in young women, and they were associated with higher histological grade. The frequency of the triple negative group (19.1%) was higher than usually reported (15%). Majority of triple negative cases had high histological grades (II or III). However, 2.1 % were well differentiated tumors. HER2-overexpressing profile predominated in the EOBC (28%) while the other group showed almost half of this frequency (15.5%). Conclusion: Expression profiles in Mexican women have special features. These findings justify a prospective clinical study in order to determine the biological behavior of the different profiles. This evaluation is important for therapeutic decisions and the quality of life in women from developing countries where expensive diagnostic techniques are not available for all patients. Key words: Breast, cancer, immunohistochemistry, molecular profiles.
    Revista latinoamericana de patología 01/2012; 50(2):72-79.
Show more